Andreas Pahl (Wilex AG)

Pahl, Andreas (Wilex 201606– Head of RnD before CSO at Heidelberg Pharma)

	Organisation	Wilex AG
	Today	Heidelberg Pharma AG (FSE: HPHA)
	Group	Heidelberg Pharma (Group)
	Former/major organisation	University of Erlangen-Nuremberg (Friedrich Alexander University, FAU)
	Product	antibody-drug conjugates (ADC) technology
	Product 2	antibody amanitin conjugate (ATAC)

Record changed: 2023-12-18

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for Andreas Pahl

[1] Heidelberg Pharma AG. (11/29/23). "Press Release: Heidelberg Pharma Announces Changes to the Executive Management Board. CEO Dr. Jan Schmidt-Brand to Retire". Ladenburg....
[2] Heidelberg Pharma AG. (3/10/22). "Press Release: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117". Ladenburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]